Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE011 (ITA) (Dr. Jansen)
· consented 2022-11-11
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 7); relationship: N
mild
assessed
2026-08-18
Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 45); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-02-07 (study day 72); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 93); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-11 (study day 165); relationship: N
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 270); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.